Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Stopped early · Phase 2

Conditions studied: Lymphoma

In brief

Primary Objective: * Overall Response Rate (ORR). Secondary Objectives: * The Duration of Response (DR) and Time to Treatment Progression (TTP) in all patients and in the responders. * Complete Responses (CR)/Complete Responses unconfirmed (CRu), and Partial Responses (PR). * Time to next anticancer therapy (TTNT).

Key facts

Study ID

NCT00493454

Run by

M.D. Anderson Cancer Center

People needed

6

Starts

2006-04-01

Expected to finish

2011-03-01

Last updated by the study team

2013-05-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or Mitomycin C) prior to study initiation, and fully recovered from acute toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.
• Previously treated patients with a histology of refractory/relapsed indolent lymphomas including: (a) Extranodal marginal lymphoma of MALT type; (b) Nodal Marginal zone B-cell lymphoma (+/- monocytoid cells); (c) Splenic marginal B-cell lymphoma (+/- villous lymphocytes).
• Signed informed consent
• Age >/= 18 years
• Expected survival >/= 3 months
• Pre-study Zubrod performance status of 0, 1, or 2
• Acceptable hematologic status within two weeks prior to patient registration, including: (a) Absolute neutrophil count ([segmented neutrophils + bands] * total white blood count (WBC)) >/= 1,500/mm\^3; (b) Platelet counts >/= 100,000/mm\^3.
• Female patients who are not pregnant or lactating
• Men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician)
• Patients previously on Phase II drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed
• Patients determined to have < 25% bone marrow involvement with lymphoma within six weeks of registration (define measurement of a bone marrow aspirate or biopsy) (This criteria must be strictly met for adequate patient safety.)
• Patient should have at least one lesion measuring >/= 2 cm in a single dimension.

You may not qualify if…

• Prior myeloablative therapies with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue.
• Platelet count< 100,000 cells/mm\^3.
• Presence of hypocellular bone marrow.
• Patients with history of failed stem cell collection.
• Prior radioimmunotherapy
• Presence of Central Nervous System (CNS) lymphoma
• Patients with HIV.
• Patients with pleural effusion
• Patients with abnormal liver function: total bilirubin > 2.0 mg/dL
• Patients with abnormal renal function: serum creatinine > 2.0 mg/dL
• Patients who have received prior external beam radiation therapy to > 25% of active bone marrow (involved field or regional)
• Patients who have received short-acting growth factor support (Leukine, Neupogen, Procrit) within 2 weeks prior to treatment or long-acting growth-factor support (Aranesp), Neulasta) within 4 weeks prior to treatment.
• Serious nonmalignant disease or infection which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives
• Major surgery, other than diagnostic surgery, within four weeks
• Evidence of transformation in the latest biopsy

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.